術前ブデソニドの術後喉痛に対する効果: 系統的レビューとメタ分析
Helal Metwalli1,2, Mohammad Najm Dadam2,3, Gam Hong Pham4
1Faculty of Human Medicine, Benha University, Benha, Egypt.
Hospital pharmacy
|September 5, 2025
まとめ
術前のブデソニドは,術後の喉の痛み (POST) の発生率と重症度を効果的に軽減します. この抗炎症剤は,内経管注入後のPOSTを予防するための実行可能で費用対効果の高い選択肢です.
科学分野:
- 麻酔科
- 薬理学について
- 呼吸器医学
背景:
- 術後の喉の痛み (POST) は,内蔵管内置術後の頻繁な合併症である.
- 抗炎症性コルチコステロイドであるブデソニドは,POST予防のために研究されています.
研究 の 目的:
- POSTの発生率と重症度を減らすためのブデソニドの有効性を評価する.
- ブデソニドとプラセボ,無介入,その他の薬剤を比較する.
主な方法:
- PRISMAのガイドラインに従って,PubMed,Scopus,Web of Science,およびコクラン図書館の体系的な文献検索を行いました.
- ランダムまたは固定効果モデルを用いたPOST発生率のメタ分析.
- ブデソニドと塩素を比較した,POSTの重症度に関する通常のロジスティック回帰分析.
主要な成果:
- プラセボと比較して,ブデソニドはPOSTの発生率を著しく低下させ,介入は行われませんでした (P < 0. 001).
- ブデソニドの有効性は,硫酸マグネシウムとケタミンと同等であった.
- ブデソニドはPOSTの重度を下げ,軽度の症例は増加し,中等重度の症例は減少した (OR0. 46).
- ブデソニドとデキサメタゾンの併用治療は,ブデソニド単独治療よりも優れた有効性を示した.
結論:
- 術前のブデソニドは,POSTの発生率と重症度を減らすのに有効な予防策です.
- 局所的抗炎症効果,費用対効果,および安全性プロフィールは,臨床使用を支持する.
- POST予防のためのブデソニドの投与と投与プロトコルを標準化するために,さらなるRCTが必要である.
関連する概念動画
01:23Chronic Pharyngitis
4.8K
Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
4.8K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
382
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
382
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
425
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
425
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
374
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
374
01:26COPD: Management Using Bronchodilators and Corticosteroids
300
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
300
01:26Tonsillitis II: Management
172
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
172